Description
RT is an investigational, lipidated peptide engineered for activity at the GIP, GLP-1 and glucagon receptors. This page presents its research identity and laboratory context without making therapeutic or dosing claims.
Potential Benefits — Research Is Ongoing
Potential benefits below relate to RT research in controlled human trials; this B&A presentation has not undergone those trials.
- Appetite control: May reduce hunger and make appetite easier to manage.
- Greater fullness: May help smaller meals feel more satisfying.
- Less food preoccupation: May reduce cravings and recurring thoughts about food.
- Weight and fat reduction: May support substantial weight reduction and improvements in abdominal fat.
- Liver-fat reduction: May help reduce excess fat stored in the liver.
- Metabolic health: May improve blood-glucose regulation and selected blood-pressure and lipid measures.
Research sources: RT obesity trial; Appetite and eating behaviour; Liver-fat study.
Research Overview
RT is being investigated in controlled clinical trials involving adults with obesity, overweight and related metabolic conditions. Study results describe trial-manufactured material, selected participants and medical supervision; they do not establish the safety, efficacy or equivalence of this B&A research pen.
Mechanism / Pathway
RT acts at three hormone receptors: GLP-1, GIP and glucagon. Researchers study this combined receptor activity in relation to appetite regulation, glucose handling and energy metabolism. It is accurately described as a triple receptor agonist; “GLP-3” is not a recognised receptor classification. [4]
Important Research Information
As of October 2026, RT remains investigational and has not been approved by a regulatory agency. Published trials do not validate commercially sold research pens for human use. Benefits, risks and long-term outcomes continue to be evaluated. [4]
Reported trial adverse effects include gastrointestinal symptoms and increases in heart rate. The presence of potential benefits does not imply that the compound is safe for unsupervised use. This page provides no dosing, titration or treatment instructions. [1]
Published Research
- Jastreboff et al. (2023): Triple-Hormone-Receptor Agonist RT for Obesity — a Phase 2 trial.
- Lilly (September 2026): Detailed Phase 3 TRIUMPH-2 results in obesity and type 2 diabetes.
- Randomised Phase 2a trial (2024): RT in metabolic dysfunction-associated steatotic liver disease.
- Lilly: RT development status and triple-agonist overview.
Scientific Profile
Research Areas
Published and ongoing research examines RT across several metabolic signalling pathways.
- Triple-receptor signalling and pathway selectivity
- Energy-balance and appetite-regulation models
- Glucose and lipid metabolism research
- Pharmacokinetics of long-acting lipidated peptides
- Body-composition and cardiometabolic outcomes in controlled trials
Product Presentation
- Format: 3 mL prefilled disposable research pen
- Pen graduation: 300 clicks
- Research compound: RT, 40 mg total research content
- Storage: Keep refrigerated at 2–8°C and protect from light
Research-Use Notice
Compare the separate RT 40 mg + Cagrilintide 5 mg prefilled pen listing, which also lists Cagrilintide. Check the complete ingredient list and total labelled contents on each page.
Warnings, Contraindications & Safety Information
Research use only. This is an evidence-limited safety summary, not a package insert, complete prescribing information or permission for self-administration. References to licensed medicines describe those specific products; they do not establish B&A product approval, equivalence or safety.
Contraindications & Who Should Avoid Exposure
A clinically validated contraindication list for this exact research presentation has not been established. That absence is not evidence of safety. Do not expose a person with a known allergy to a labelled ingredient or excipient.
Warnings & Precautions
RT trials have reported gastrointestinal adverse events and increased heart rate. These findings do not define a complete safety profile for this research product. Pregnancy, breastfeeding, use in children, significant illness and interactions remain insufficiently characterised. Do not assume that precautions for an approved GLP-1 medicine establish safety for RT.
Possible Adverse Reactions
Clinical trials reported nausea, diarrhoea, vomiting, constipation and heart-rate increases. The frequency and severity for this B&A presentation are unknown.
Drug & Supplement Interactions
Drug and supplement interactions have not been adequately characterised for this presentation. Do not assume that combining it with prescription medicines, hormones or other research compounds is safe. Give a clinician the full ingredient list if exposure has occurred.
When to Seek Urgent Help
Seek emergency care for difficulty breathing, swelling of the face or throat, collapse, severe persistent abdominal pain, or repeated vomiting with inability to keep fluids down. Stop further exposure and show the clinician the product label and ingredient list.
Handling & Storage Cautions
Follow the actual product label and batch-specific expiry information. Do not use damaged, contaminated or unexpectedly changed material. A clear appearance, refrigeration or addition of bacteriostatic water does not prove sterility, compatibility or a safe shelf life. Do not share needles, pens or opened material between people.
Safety references: RT clinical trial. Information reviewed 20 October 2026.
Reviews
There are no reviews yet.